Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Roubaix – page 16

1 745 clinical trials in Roubaix, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Roubaix at a glance
1 745
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 745 trials in Roubaix

Open in trial search

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.

Comparing the timing of etoposide and dexamethasone treatment for patients with severe sporadic hemophagocytic lymphohistiocytosis in intensive care.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Etoposide
  • Sponsor:Assistance Publique Hopitaux De Paris

Acute leukaemia

Recruiting

A study of enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Enzomenib
  • Sponsor:Sumitomo Pharma America Inc.

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tirzepatide
  • Sponsor:Eli Lilly & Co.

Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Centre Leon Berard

Evaluation of Safety and Efficacy of MK-2870 and Paclitaxel in Second-Line Treatment of Advanced/Metastatic Gastroesophageal Adenocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sunitinib
  • Sponsor:Glaxosmithkline Research & Development Limited

Hepatitis D

Recruiting

A study comparing brelovitug to bulevirtide for treating chronic hepatitis delta infection in patients currently receiving bulevirtide

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Mirum Pharmaceuticals Inc.

A Study of Atumelnant for Children with Congenital Adrenal Hyperplasia

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Coramitug
  • Sponsor:Novo Nordisk A/S

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Roubaix

What the registry says about research in the country

01 Hematologic Oncology

Research focusing on innovative treatments for Multiple Myeloma and various forms of leukemia, including comparative studies of novel therapeutic combinations and traditional approaches.

  • Multiple Myeloma therapies
  • Acute Myeloid Leukemia treatments
  • Myeloproliferative disorders

Studies evaluating treatment effectiveness in newly diagnosed patients and those with advanced disease stages.

02 Neurological Disorders

Innovative research exploring potential treatments for Alzheimer's disease, including studies on caffeine's effects on cognitive function in early-to-moderate stage patients.

  • Cognitive decline prevention
  • Novel therapeutic approaches
  • Disease progression monitoring

Focus on non-pharmacological interventions and their impact on disease progression.

03 Respiratory Medicine

Clinical investigations into severe asthma management and pulmonary infections, including studies on treatment optimization and novel therapeutic approaches.

  • Severe allergic asthma control
  • Mycobacterium avium complex treatment
  • Medication withdrawal studies

Evaluation of long-term treatment strategies and comparative medication studies.

04 Cardiovascular and Renal Studies

Research examining hypertension management in patients with chronic kidney disease, along with studies on thrombo-embolic complications prevention.

  • Blood pressure management
  • Kidney disease progression
  • Cardiovascular risk reduction

Focus on optimizing treatment strategies for complex cardiovascular conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.